MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Debt-to-Equity : 0.01 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is MoonLake Immunotherapeutics Debt-to-Equity?

MoonLake Immunotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.31 Mil. MoonLake Immunotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.50 Mil. MoonLake Immunotherapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $495.68 Mil. MoonLake Immunotherapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for MoonLake Immunotherapeutics's Debt-to-Equity or its related term are showing as below:

MLTX' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.29 Med: 0.01 Max: 0.01
Current: 0.01

During the past 3 years, the highest Debt-to-Equity Ratio of MoonLake Immunotherapeutics was 0.01. The lowest was -1.29. And the median was 0.01.

MLTX's Debt-to-Equity is ranked better than
99.91% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs MLTX: 0.01

MoonLake Immunotherapeutics Debt-to-Equity Historical Data

The historical data trend for MoonLake Immunotherapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MoonLake Immunotherapeutics Debt-to-Equity Chart

MoonLake Immunotherapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Equity

-1.29

0.01

MoonLake Immunotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial						0.01	0.01	-	-	0.01

Competitive Comparison of MoonLake Immunotherapeutics's Debt-to-Equity

For the Biotechnology subindustry, MoonLake Immunotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MoonLake Immunotherapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where MoonLake Immunotherapeutics's Debt-to-Equity falls into.

MoonLake Immunotherapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

MoonLake Immunotherapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.306	+	2.5)	/	495.676
	=	0.01

MoonLake Immunotherapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.306	+	2.5)	/	495.676
	=	0.01

MoonLake Immunotherapeutics (NAS:MLTX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

MoonLake Immunotherapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of MoonLake Immunotherapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MoonLake Immunotherapeutics (NAS:MLTX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MLTX:Mexico

Address

Dorfstrasse 29, Zug, CHE, 6300

Website

https://www.moonlaketx.com

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Executives

Matthias Bodenstedt	officer: Chief Financial Officer	DORFSTRASSE 29, ZUG V8 6300
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iv Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Simon Sturge	director	DORFSTRASSE 29, ZUG V8 6300
Kristian Reich	officer: Chief Scientific Officer	DORFSTRASSE 29, ZUG V8 6300
Santos Da Silva Jorge	director, officer: Chief Executive Officer	DORFSTRASSE 29, ZUG V8 6300
Bvf Partners L P/il	director, 10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Andrew John Phillips	director	C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Ramnik Xavier	director	DORFSTRASSE 29, ZUG V8 6300
Spike Loy	director	DORFSTRASSE 29, ZUG V8 6300
Kara Lassen	director	DORFSTRASSE 29, ZUG V8 6300